Market Place
Sourcing Support
Cybin Completes Acquisition of Small Pharma Inc.
23 Oct 2023 //
BUSINESSWIRE
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
19 Oct 2023 //
GLOBENEWSWIRE
Small Pharma Obtains Final Order Approving Arrangement
17 Oct 2023 //
BUSINESSWIRE
Small Pharma Announces Voting Results from Annual General and Special Meeting
12 Oct 2023 //
GLOBENEWSWIRE
Disposition of Common Shares of Small Pharma Inc.
02 Oct 2023 //
GLOBENEWSWIRE
Small Pharma Reports Positive Top-line Data from SPL026
27 Sep 2023 //
BUSINESSWIRE
Small Pharma Reports Positive Top-line Data from SPL026 Interaction Study
26 Sep 2023 //
GLOBENEWSWIRE
Cybin to Acquire Small Pharma Inc.
28 Aug 2023 //
BUSINESSWIRE
Small Pharma Reports Fiscal First Quarter 2024 Highlights
27 Jul 2023 //
GLOBENEWSWIRE
Small Pharma Announces Management Team Change
05 Jul 2023 //
GLOBENEWSWIRE
Small Pharma Announces SPL028 R&D Strategy Update
05 Jul 2023 //
GLOBENEWSWIRE
Small Pharma Reports Financial Results for the Fiscal Year Ended Feb 28, 2023
28 Jun 2023 //
GLOBENEWSWIRE
Small Pharma Announces Developments In Intellectual Property Portfolio
25 May 2023 //
GLOBENEWSWIRE
Small Pharma to Present Upcoming CINP World Congress of Neuropsychopharmacology
03 May 2023 //
GLOBENEWSWIRE
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
04 Apr 2023 //
GLOBENEWSWIRE
Small Pharma to Host Roundtable Event with Key Opinion Leaders in Psychiatry
07 Mar 2023 //
GLOBENEWSWIRE
Small Pharma to Present at Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
Small Pharma begins phase 1 mental health therapy trial
16 Feb 2023 //
PHARMATIMES
First Subject Dosed in Small Pharma`s First-in-Human PI Trial with SPL028
15 Feb 2023 //
GLOBENEWSWIRE
Small Pharma Announces Update on Intellectual Property Portfolio
01 Feb 2023 //
GLOBENEWSWIRE
Small Pharma’s depressive disorder therapy trial meets primary goal
26 Jan 2023 //
CLINICAL TRIALS ARENA
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
25 Jan 2023 //
GLOBENEWSWIRE
Small Pharma To Announce Results of SPL026 PIIa Trial for Depressive Disorder
24 Jan 2023 //
GLOBENEWSWIRE
First Patient Dosed in Small Pharma`s Phase I Study of SPL026
09 Jan 2023 //
GLOBENEWSWIRE
Small Pharma Announces Completion of SPL026 Phase IIa Trial
22 Dec 2022 //
GLOBENEWSWIRE
First Patient Dosed in Small Pharma’s Drug Interaction Study
15 Dec 2022 //
GLOBENEWSWIRE
Small Pharma To Support University College London Project on Neuroplasticity
14 Dec 2022 //
GLOBENEWSWIRE
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
08 Dec 2022 //
GLOBENEWSWIRE
Small Pharma Receives Approval for First-In-Human Phase I Trial With SPL028
31 Oct 2022 //
GLOBENEWSWIRE
Small Pharma Reports Fiscal Second Quarter 2023 Highlights
14 Oct 2022 //
GLOBENEWSWIRE
Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Clinical Trial
19 Sep 2022 //
GLOBENEWSWIRE
Small Pharma Announces TSXV Approval of Normal Course Issuer Bid
18 Aug 2022 //
GLOBENEWSWIRE
Small Pharma Receives Approval for DMT
15 Aug 2022 //
GLOBENEWSWIRE
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy
26 Jul 2022 //
GLOBENEWSWIRE
George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer
18 Jul 2022 //
GLOBENEWSWIRE
Small Pharma Reports Fiscal First Quarter 2023 Highlights
15 Jul 2022 //
GLOBENEWSWIRE
Small Pharma to Participate in the H.C. Wainwright Conference on June 27
22 Jun 2022 //
GLOBENEWSWIRE
Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022
09 Jun 2022 //
GLOBENEWSWIRE
Small Pharma To Present at the Jefferies Healthcare Conference
30 May 2022 //
GLOBENEWSWIRE
Small Pharma Shares Business Update Ahead of Annual Financial Results
25 May 2022 //
GLOBENEWSWIRE
Small Pharma to Participate in the PSYCH Symposium: London 2022
05 May 2022 //
GLOBENEWSWIRE
Small Pharma Expands Commercial Portfolio With DMT-Based Psychedelic Assets
10 Mar 2022 //
GLOBENEWSWIRE
Small Pharma to Participate in the 34th Annual Roth Conference
09 Mar 2022 //
GLOBENEWSWIRE
DMT-Assisted Therapy in MDD Shows Consistent Quality of Psychedelic Response
22 Feb 2022 //
BUSINESSWIRE
Small Pharma Reports Fiscal Third Quarter 2021 Highlights
31 Jan 2022 //
GLOBENEWSWIRE
Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design
15 Nov 2021 //
GLOBENEWSWIRE
Small Pharma Reports Second Quarter Highlights
01 Nov 2021 //
GLOBENEWSWIRE
European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio
25 Oct 2021 //
GLOBENEWSWIRE
Small Pharma’s Phase IIa DMT-assisted therapy begins
21 Oct 2021 //
PHARMAFILE
Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT
21 Oct 2021 //
GLOBENEWSWIRE
Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility
20 Oct 2021 //
GLOBENEWSWIRE
First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial
19 Oct 2021 //
GLOBENEWSWIRE
Small Pharma Successfully Completes PhI Clinical Trial Of DMT & Psychotherapy
21 Sep 2021 //
PRNEWSWIRE
Small Pharma Included in AdvisorShares® Newly Launched Psychedelics ETF
20 Sep 2021 //
GLOBENEWSWIRE
Small Pharma Announces Engagement of Investor Relations Provider
15 Sep 2021 //
GLOBENEWSWIRE
Small Pharma Announces Appointment of Lyne Fortin as Chair of the Board
27 Aug 2021 //
GLOBENEWSWIRE
Small Pharma To Present At Canaccord Genuity`s Annual Growth Conference
09 Aug 2021 //
PRNEWSWIRE
Small Pharma To Present At Canaccord Genuity`s Annual Growth Conference
09 Aug 2021 //
PRNEWSWIRE
Small Pharma Establishes Psychedelicassisted Therapy Training Program
21 Jul 2021 //
PRNEWSWIRE
Small Pharma To Present Progress And Innovations In DMT-Assisted Therapy
26 Jun 2021 //
PR NEWSWIRE
